Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2022, 16:49.
Patrick Lin - 06 Apr 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 06 Apr 2022
- Net transaction value
- +$6,587
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2022, 16:49:49 UTC
- Prior SEC filing
- 11 Apr 2022
- Next SEC filing
- 19 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 08 Apr 2022.
Change
- Previous filing in this sequence was filed on 11 Apr 2022.
- Current net transaction value: +$6,587.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Purchase
- Transaction value
- $3,752
- Shares
- +1,200
- Change %
- +0.28%
- Price
- $3.13
- Shares after
- 430,590
- Date
- 06 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
PCSA
transaction
Common Stock
Purchase
- Transaction value
- $2,835
- Shares
- +800
- Change %
- +0.19%
- Price
- $3.54
- Shares after
- 431,390
- Date
- 07 Apr 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.18, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.45 to $3.60, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.